Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) FCF Margin (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed FCF Margin for 3 consecutive years, with 795.4% as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, FCF Margin fell 40163.0% year-over-year to 795.4%, compared with a TTM value of 988.28% through Dec 2024, up 177552.0%, and an annual FY2024 reading of 988.28%, up 177552.0% over the prior year.
  • FCF Margin was 795.4% for Q2 2024 at Oramed Pharmaceuticals, down from 249.66% in the prior quarter.
  • Across five years, FCF Margin topped out at 249.66% in Q1 2024 and bottomed at 1377.18% in Q1 2022.
  • Average FCF Margin over 3 years is 714.32%, with a median of 829.23% recorded in 2023.
  • Peak annual rise in FCF Margin hit 111273bps in 2024, while the deepest fall reached -40163bps in 2024.
  • Year by year, FCF Margin stood at 925.88% in 2022, then surged by 57bps to 393.77% in 2023, then crashed by -102bps to 795.4% in 2024.
  • Business Quant data shows FCF Margin for ORMP at 795.4% in Q2 2024, 249.66% in Q1 2024, and 393.77% in Q2 2023.